advertisement
Lin Z 9
Showing records 1 to 9 | Display all abstracts from Lin Z128812 Long-term outcomes of vitrectomy for proliferative diabetic retinopathy: a real world study in China
Mei J
International Ophthalmology 2025; 45: 366
128774 Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
Lin Z; Xue J
Frontiers in pharmacology 2025; 16: 1623921
128812 Long-term outcomes of vitrectomy for proliferative diabetic retinopathy: a real world study in China
Zhou H
International Ophthalmology 2025; 45: 366
128774 Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
Yang M
Frontiers in pharmacology 2025; 16: 1623921
128812 Long-term outcomes of vitrectomy for proliferative diabetic retinopathy: a real world study in China
Deng C; Wang S
International Ophthalmology 2025; 45: 366
128774 Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
Yu X
Frontiers in pharmacology 2025; 16: 1623921
128812 Long-term outcomes of vitrectomy for proliferative diabetic retinopathy: a real world study in China
Guo B
International Ophthalmology 2025; 45: 366
128774 Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
Zhong J
Frontiers in pharmacology 2025; 16: 1623921
128812 Long-term outcomes of vitrectomy for proliferative diabetic retinopathy: a real world study in China
Lin W; Lin Z; Lin K; Wu R
International Ophthalmology 2025; 45: 366
